Further expansion of operations centered on the healthcare business
First written in FY2016. 31 of 42 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-08-07.
4 other companies' latest entry also says "Advanced".
- FY2026WorsenedAnnual report
「Consolidated gastrointestinal endoscopy solutions revenue was ¥697.359 billion, up 3.5% year on year, and operating profit was ¥136.359 billion, down 20.5%. Consolidated surgical intervention revenue was ¥313.109 billion, down 3.0%, and the business reported an operating loss of ¥14.986 billion, compared with operating profit of ¥15.265 billion in the prior period.」
For the full year under the new segments, gastrointestinal endoscopy solutions posted higher revenue but lower operating profit, while surgical intervention posted lower revenue and moved from operating profit to an operating loss, worsening profitability in the medical business. - FY2026-H1WorsenedAnnual report
「Consolidated gastrointestinal endoscopy solutions revenue was ¥307.041 billion, down 4.8% year on year, and operating profit was ¥53.444 billion, down 31.1%. Consolidated surgical intervention revenue was ¥147.201 billion, down 2.7%, and the business reported an operating loss of ¥4.182 billion, compared with operating profit of ¥2.266 billion in the previous interim consolidated accounting period.」
Regarding expansion in the medical business, both segments posted lower revenue during the current interim consolidated accounting period, and surgical intervention reported an operating loss. - FY2025AdvancedAnnual report
「Consolidated endoscopy revenue was ¥636.144 billion, up 8.4% year on year, and operating profit was ¥141.398 billion, up 35.1%. Consolidated therapeutic-device revenue was ¥360.658 billion, up 6.9%, and operating profit was ¥61.453 billion, compared with an operating loss of ¥8.466 billion in the prior period.」
Endoscopy posted higher revenue and operating profit, while therapeutic devices posted higher revenue and moved from an operating loss to operating profit, advancing the medical business's scale and profitability. - FY2025-H1AdvancedAnnual report
「Consolidated endoscopy revenue was ¥298.706 billion, up 10.3% year on year, and operating profit was ¥62.554 billion, up 22.9%. Consolidated therapeutic-device revenue was ¥175.038 billion, up 9.6%, and operating profit was ¥26.846 billion, compared with an operating loss of ¥28.542 billion in the same period of the prior year.」
During the interim consolidated accounting period, both the endoscopy and therapeutic-device businesses posted higher revenue, and operating profit also improved. - FY2024AdvancedAnnual report
「Consolidated endoscopy revenue was ¥586.617 billion, up 6.3% year on year, and operating profit was ¥104.684 billion, down 31.5%. Consolidated therapeutic-device revenue was ¥337.331 billion, up 6.0%, and the business reported an operating loss of ¥8.466 billion, compared with operating profit of ¥63.692 billion in the prior period.」
Both the endoscopy and therapeutic-device businesses in the medical segment posted higher revenue and expanded in scale, but profitability deteriorated due to quality-related costs, losses related to VMT and other factors. - FY2024-Q3AdvancedAnnual report
「Consolidated endoscopy revenue was ¥419.316 billion, up 5.1% year on year, and operating profit was ¥83.580 billion, down 24.5%.」
For the nine months ended in the third quarter, endoscopy revenue increased 5.1% and therapeutic-device revenue increased 5.7%, continuing the expansion in medical business scale. Operating profit in both businesses, meanwhile, deteriorated due to quality-related costs and other factors. - FY2024-Q1AdvancedAnnual report
「Consolidated endoscopy revenue was ¥127.138 billion, up 8.8% year on year, and operating profit was ¥22.177 billion, down 10.7%. Consolidated therapeutic-device revenue was ¥77.156 billion, up 6.6%, and operating profit was ¥9.681 billion, down 27.5%.」
Both the endoscopy and therapeutic-device businesses posted higher revenue. Operating profit, meanwhile, declined due to quality and regulatory compliance costs, costs to strengthen the business operating platform and other factors. - FY2023AdvancedAnnual report
「Consolidated endoscopy revenue was ¥551.823 billion, up 19.6% year on year, and operating profit was ¥152.769 billion, up 14.7%. Consolidated therapeutic-device revenue was ¥318.207 billion, up 15.5%, and operating profit was ¥63.692 billion, up 4.7%.」
Both the endoscopy and therapeutic-device businesses comprising the medical business continued to post higher full-year revenue and operating profit, further expanding business scale. - FY2023-Q3AdvancedAnnual report
「Consolidated endoscopy revenue was ¥398.990 billion, up 19.6% year on year, and operating profit was ¥110.703 billion, up 20.9%. Consolidated therapeutic-device revenue was ¥233.942 billion, up 14.8%, and operating profit was ¥48.116 billion, up 9.7%.」
For the nine months ended in the third quarter, the endoscopy business posted 19.6% revenue growth and 20.9% operating profit growth, while the therapeutic-device business posted 14.8% revenue growth and 9.7% operating profit growth. - FY2023-Q2AdvancedAnnual report
「Consolidated endoscopy revenue was ¥258.472 billion, up 17.2% year on year, and operating profit was ¥68.899 billion, up 11.8%. Consolidated therapeutic-device revenue was ¥152.935 billion, up 14.9%, and operating profit was ¥29.788 billion, down 1.6%.」
For the cumulative period through Q2 of FY2023, both the endoscopy and therapeutic-device businesses posted higher revenue, and the medical business continued to expand in scale. Endoscopy posted higher operating profit, while therapeutic devices posted higher revenue but lower operating profit. - FY2023-Q1AdvancedAnnual report
「Consolidated endoscopy revenue was ¥116.857 billion, up 16.8% year on year, and operating profit was ¥24.834 billion, up 9.6%. Consolidated therapeutic-device revenue was ¥72.365 billion, up 13.7%, and operating profit was ¥13.357 billion, down 5.1%.」
Both the endoscopy and therapeutic-device businesses comprising the medical business posted higher revenue. Endoscopy posted higher revenue and operating profit, while therapeutic devices posted higher revenue but lower operating profit. - FY2022AdvancedAnnual report
「Consolidated endoscopy revenue was ¥461.547 billion, up 17.2% year on year, and operating profit was ¥133.204 billion, up 34.9%. Consolidated therapeutic-device revenue was ¥275.586 billion, up 18.9%, and operating profit was ¥60.826 billion, up 99.0%.」
Both the endoscopy and therapeutic-device businesses comprising the medical business posted higher revenue and operating profit, advancing expansion in business scale and profitability improvement. - FY2022-Q3AdvancedAnnual report
「Consolidated endoscopy revenue was ¥333.701 billion, up 20.6% year on year, and operating profit was ¥91.600 billion, up 23.9%.」
Regarding expansion in the medical business, the endoscopy business posted higher revenue and operating profit. The therapeutic-device business also reported revenue of ¥203.714 billion, up 24.3% year on year, indicating continued recovery and expansion in the medical field. - FY2022-Q2AdvancedAnnual report
「Consolidated endoscopy revenue was ¥220.565 billion, up 28.7% year on year, and operating profit was ¥61.645 billion, up 45.6%. Consolidated therapeutic-device revenue was ¥133.101 billion, up 31.0%, and operating profit was ¥30.262 billion, up 204.9%.」
As the businesses recovered from the impact of COVID-19, both the endoscopy and therapeutic-device businesses posted substantial increases in revenue and operating profit, further restoring the medical business's growth track record. - FY2022-Q1AdvancedAnnual report
「Consolidated endoscopy revenue was ¥100.014 billion, up 34.6% year on year, and operating profit was ¥22.654 billion, up 82.4%. Consolidated therapeutic-device revenue was ¥63.646 billion, up 48.1%, and operating profit was ¥14.072 billion, up 284.2%.」
Against a backdrop of recovery from the impact of COVID-19, the endoscopy and therapeutic-device businesses posted substantial increases in revenue and operating profit, restoring the medical business's growth track record. - FY2021WorsenedAnnual report
「Consolidated endoscopy revenue was ¥419.466 billion, down 1.5% year on year, and operating profit was ¥104.705 billion, down 4.3%. Consolidated therapeutic-device revenue was ¥206.040 billion, down 4.6%, and operating profit was ¥24.633 billion, down 5.9%.」
For FY2021, both the endoscopy and therapeutic-device businesses posted lower revenue and operating profit, reversing the prior year's expansion in business scale centered on the medical business. - FY2021-Q3WorsenedAnnual report
「Consolidated endoscopy revenue was ¥294.489 billion, down 6.5% year on year, and operating profit was ¥76.753 billion, down 16.2%.」
The endoscopy, therapeutic-device and scientific businesses all posted lower revenue and operating profit for the nine months ended in the third quarter due to fewer procedures resulting from COVID-19 and restrictions on promotional activities, worsening the growth track record centered on the medical business. - FY2021-Q2WorsenedAnnual report
「Consolidated endoscopy revenue was ¥182.044 billion, down 12.0% year on year, and operating profit was ¥42.054 billion, down 29.7%. Consolidated therapeutic-device revenue was ¥90.913 billion, down 15.8%, and operating profit was ¥10.208 billion, down 32.9%.」
Both the endoscopy and therapeutic-device businesses posted lower revenue and operating profit in the first half due to fewer procedures resulting from COVID-19 and restrictions on promotional activities. - FY2021-Q1WorsenedAnnual report
「Consolidated therapeutic-device revenue was ¥38.1 billion, down 26.8% year on year, and operating profit was ¥1.449 billion, down 74.5%.」
In the therapeutic-device business, revenue declined 26.8% and operating profit declined 74.5% due to fewer procedures resulting from postponed or canceled surgeries and restrictions on customer visits and business negotiations. - FY2021-Q1WorsenedAnnual report
「Consolidated endoscopy revenue was ¥79.198 billion, down 17.0% year on year, and operating profit was ¥14.631 billion, down 33.2%.」
Both the endoscopy and therapeutic-device businesses posted lower revenue and operating profit due to fewer procedures resulting from COVID-19 and restrictions on customer visits and business negotiations, temporarily reversing the medical business's growth track record. - FY2020RaisedAnnual report
「The strategic objective of the current management strategy is to grow into a world-leading medtech company, deliver benefits through innovative value to customers including patients and healthcare professionals, medical institutions and the healthcare economy, and contribute to the health of people worldwide. The core elements for business growth and improved profitability are defined as follows.」
The previous growth policy centered on the medical business has been expanded to a strategic objective of becoming a world-leading medtech company, with specific growth targets set for the endoscopy and therapeutic-device businesses. - FY2020-Q3AdvancedAnnual report
「Consolidated endoscopy revenue was ¥315.123 billion, up 3.7% year on year, and operating profit was ¥91.580 billion, up 39.2%. Consolidated therapeutic-device revenue was ¥163.589 billion, up 1.9%, and operating profit was ¥22.537 billion, up 8.5%.」
For the nine months ended in the third quarter, both the endoscopy and therapeutic-device businesses posted higher revenue and operating profit following the reorganization of the medical business. - FY2020-Q2AdvancedAnnual report
「Consolidated endoscopy revenue was ¥206.789 billion, up 3.0% year on year, and operating profit was ¥59.816 billion, up 43.8%. Consolidated therapeutic-device revenue was ¥108.025 billion, up 3.1%, and operating profit was ¥15.223 billion, up 16.2%.」
Following the reorganization of the medical business, both the endoscopy and therapeutic-device businesses posted higher revenue and operating profit than in the same period of the prior year. - FY2020-Q1AdvancedAnnual report
「Consolidated endoscopy revenue was ¥95.410 billion, up 2.7% year on year, and operating profit was ¥21.918 billion, up 1.8%. Consolidated therapeutic-device revenue was ¥52.056 billion, up 2.1%, and operating profit was ¥5.676 billion, down 3.1%.」
Following the reorganization of the medical business, results were disclosed separately for the endoscopy and therapeutic-device businesses, and revenue increased year on year in both businesses. - FY2019AdvancedAnnual report
「Consolidated medical revenue was ¥634.301 billion, up 2.9% year on year, while operating profit was ¥111.934 billion, down 8.1% year on year.」
Medical revenue increased 2.9%, and business scale continued to expand. Operating profit, meanwhile, declined 8.1% due to expenses and other costs associated with the execution of the plea agreement. - FY2019-Q3AdvancedAnnual report
「Consolidated medical revenue was ¥464.435 billion, up 3.8% year on year, while operating profit was ¥86.535 billion, down 1.4% year on year.」
For the nine months ended in the third quarter, medical revenue increased 3.8%, and business scale continued to expand. Operating profit, meanwhile, declined 1.4% due to expenses recognized in connection with the execution of the plea agreement. - FY2019-Q2AdvancedAnnual report
「Consolidated medical revenue was ¥305.638 billion, up 5.7% year on year, while operating profit was ¥54.690 billion, down 1.3% year on year.」
Medical revenue increased 5.7% year on year in the first half, and business scale continued to expand. Operating profit, meanwhile, declined 1.3% due to the provision for estimated losses related to the U.S. Department of Justice investigation. - FY2019-Q1AdvancedAnnual report
「Consolidated medical revenue was ¥143.916 billion, up 7.1% year on year, while operating profit was ¥27.382 billion, up 18.0% year on year.」
In the first quarter, medical revenue and operating profit increased 7.1% and 18.0%, respectively, and business scale continued to expand. - FY2018AdvancedAnnual report
「Consolidated medical revenue was ¥616.331 billion, up 8.1% year on year, while operating profit was ¥121.784 billion, up 6.2% year on year.」
For the full year, medical revenue and operating profit increased 8.1% and 6.2%, respectively, and business scale continued to expand. - FY2018-Q3AdvancedAnnual report
「Consolidated medical revenue was ¥447.273 billion, up 9.0% year on year, while operating profit was ¥87.772 billion, down 0.3% year on year.」
For the nine months ended in the third quarter, medical revenue increased 9.0%, indicating continued expansion in business scale. Operating profit declined 0.3%, remaining broadly in line with the prior year. - FY2018-Q2AdvancedAnnual report
「Consolidated medical revenue was ¥289.254 billion, up 6.4% year on year, while operating profit was ¥55.384 billion, down 7.3% year on year.」
Medical revenue increased 6.4% year on year in the first half, indicating continued expansion in business scale. Operating profit, meanwhile, declined 7.3%. - FY2018-Q1AdvancedAnnual report
「Consolidated medical revenue was ¥134.436 billion, up 2.8% year on year, while operating profit was ¥23.197 billion, down 8.6% year on year.」
Although medical operating profit declined in the first quarter, revenue increased 2.8% year on year, indicating continued expansion in business scale. - FY2017AdvancedAnnual report
「Medical revenue declined due to the stronger yen, but increased 4% year on year on a local-currency basis excluding the impact of foreign exchange. In gastrointestinal endoscopy, sales of the core endoscopy systems EVIS EXERA Ⅲ (EVIS EXERA Three) and EVIS LUCERA ELITE (EVIS LUCERA Elite) both remained strong.」
For the full year, medical revenue declined including the impact of the stronger yen, but increased 4% on a local-currency basis, with strong sales of core endoscopy products reported. - FY2017-Q3AdvancedAnnual report
「Medical revenue declined due to the stronger yen, but increased 4% year on year on a local-currency basis excluding the impact of foreign exchange. In gastrointestinal endoscopy, sales of the core endoscopy systems EVIS EXERA Ⅲ (EVIS EXERA Three) and EVIS LUCERA ELITE (EVIS LUCERA Elite) remained strong. In surgery, the integrated endoscopy video system VISERA ELITE (VISERA Elite), which supports endoscopic surgery, and the 3D endoscopy system performed steadily, while sales of THUNDERBEAT, an integrated bipolar radiofrequency and ultrasonic energy device, continued to grow. In therapeutic devices, sales were strong for products including the VisiGlide 2 disposable guidewire, used in endoscopic diagnosis and treatment of the pancreatic and bile ducts. Medical operating profit declined due to the stronger yen, but excluding the impact of foreign exchange, increased 6% year on year as each business area remained firm.」
For the nine months ended in the third quarter, medical revenue and operating profit increased 4% and 6%, respectively, excluding the impact of foreign exchange, while strong sales of key products continued. - FY2017-Q2AdvancedAnnual report
「Medical revenue declined due to the stronger yen, but increased 3% year on year on a local-currency basis excluding the impact of foreign exchange. Medical operating profit declined due to the stronger yen, but excluding the impact of foreign exchange, increased 2% year on year as each business area remained firm.」
Including the impact of the stronger yen, medical revenue and operating profit declined, but both increased year on year excluding the impact of foreign exchange. - FY2016First statedAnnual report
「In the Medical business, we will actively invest in the Gastroenterology and Respiratory, Surgical, Urology and Gynecology, Ear, Nose and Throat, and Medical Services business units, with the provision of value through early diagnosis and minimally invasive treatment as the pillars of growth, and aim to further expand the scale of the business.」
The company specified investment in 5 business units, with early diagnosis and minimally invasive treatment as the pillars of growth.